Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC
March 1st 2024Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.
Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC
November 21st 2022Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
SBRT Induces Improved Disease Control Rates Compared With CRT in Central/Peripheral Lung Cancer
November 16th 2022Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non–small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Post-Operative iSRT Plus Degarelix Yields Improved MFS in Prostate Cancer With Elevated PSA
October 28th 2022Patients with prostate cancer who experienced an increase in prostate-specific antigen level after radical prostatectomy appeared to benefit from a short course of androgen deprivation therapy after post-operative immediate salvage radiotherapy.
High Detection Rates Achieved With 18F-rhPSMA-7.3 PET in Recurrent Prostate Cancer
October 26th 2022Data from the phase 3 SPOTLIGHT trial indicated that 18F-rhPSMA-7.3 PET yielded a positive detection rate in patients with recurrent prostate cancer, and increased along with prostate-specific antigen level.